{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:43:43Z","timestamp":1790790223922,"version":"4.1.0"},"reference-count":32,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,2,1]]},"abstract":"<jats:p>Introduction. Prader-Willi syndrome (PWS) is characterized by obesity, hypotonia, hypogonadism, hyperphagia, short stature, and a neurobehavioral profile that includes cognitive deficits, learning problems, and behavioral difficulties that increase in both quantity and severity over time. PWS results from an alteration in the molecular composition of a critical region of C#15q. Morbid obesity resulting from hyperphagia is amplified by decreased energy expenditure and reduced physical activity. The hyperphagia has proven refractory to all psychopharmocologic intervention; the behavioral components are equally resistant to psychotropic intervention. PWS patients\u2019 body composition resembles that of individuals with growth hormone (GH) deficiency, including short stature and reduced lean body mass with concomitant increased fat mass. We hypothesized that GH administration to children with PWS, in addition to stimulating linear growth, would improve body composition, increase energy expenditure and fat utilization, and improve muscle strength, physical agility, and pulmonary function. Two recent reports from this study document significant positive effects of GH treatment on these children\u2019s physical parameters measured in a 2-year, controlled study. However, the behavioral impact of GH treatment in this population remains incompletely described.<\/jats:p>\n               <jats:p>A psychosocial burden, including emotional, behavioral, and cognitive disturbances associated with short stature, has been previously described in a non-PWS population with GH deficiency and idiopathic short stature. An impaired quality of life and psychosocial status is also documented in otherwise normal adults with GH deficiency. In both populations, growth hormone replacement therapy (GHRT) is reported to improve alertness, activity level, endurance, irritability, tendency to worry, and extroversion resulting in better personal relationships with fewer conflicts. This report focuses on that portion of the study investigating the behavioral and psychosocial outcomes accompanying increased stature and improved physical status for persons with PWS treated with GHRT. We hypothesized that, as in other populations, GHRT for persons with PWS would have a significant positive effect on their psychosocial status as well as an improvement in their growth parameters.<\/jats:p>\n               <jats:p>Methods. A 2-year, controlled study with control group crossover in the second year was used. Fifty-four consecutive children with genetically confirmed PWS were enrolled. Patients were 4 to 16 years of age at time of enrollment, had skeletal maturation &amp;lt;13 for girls and &amp;lt;15 for boys; all but 3 participants remained prepubertal (Tanner stage 1) throughout the study. Children who had previous therapy with GH were excluded, as were children with a scoliosis &amp;gt;20\u00b0. After a 6-month growth assessment were randomized into a 60:40 treatment:control ratio. Treatment consisted of Nutropin (Genentech), 1 mg\/m2\/day.<\/jats:p>\n               <jats:p>A modified Offord Survey Diagnostic Instrument (SDI) was used to monitor behavior at 6-month intervals. The SDI is a 165-item behavioral checklist with items rated on a scale of 0 = Never or Not True, 1 = Sometimes or Somewhat True, and 2 = Often or Very True. The items are balanced between positively and negatively scored items. The present instrument was designed to derive diagnoses for the following Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition categories: Depression, Obsessive-Compulsive Disorder, Anxiety Disorder, Somatization Disorder, Conduct Disorder, and Attention-Deficit\/Hyperactivity Disorder. The SDI was modified to include 10 items specifically inquiring about PWS (eg, denies having PWS, picks excessively at skin, nose, or other body parts). Because diagnoses are not mutually exclusive, an individual can meet criteria for 1 or more diagnostic categories.<\/jats:p>\n               <jats:p>The SDI contains a second section measuring behavior functioning in the school environment, in the family, and in personal and social relationships. A wider scoring range is used and is question-specific. Parallel forms of this measure are available for parents, teachers, and the child him\/herself. We gathered data from both parents and teachers at 6-month intervals. No questionnaire was scored until the completion of the entire study to avoid any possibility of an inadvertent \u201cfeedback\u201d or \u201cself-fulfilling prophecy\u201d effect. All questionnaires were scored by a Bachelor\u2019s level research assistant blind to study assignment.<\/jats:p>\n               <jats:p>Family stress was monitored with the Family Inventory of Life Events. At study completion, the impact of GH was measured with a 13-item summary interview adapted from Wiren et al. After completion of all final study visits, a single research assistant blind to treatment assignment interviewed all families by phone. This method was chosen to minimize any positively biased demand characteristics.<\/jats:p>\n               <jats:p>Results. Both between-group and within-group contrasts were computed for baseline, 12 (time 1) and 24 month (time 2) measures. Because behavioral deterioration, as well as improvement, was a possibility, a 2-tailed hypothesis test was used for all comparisons. No differences were found between treatment and control groups, nor within groups across measurement points for attentional symptoms, anxiety, obsessive-compulsive complex, violence, or psychotic symptoms. Similarly, no differences were noted between groups on depressive symptoms; however, a significant positive effect (reduction of depressive symptoms) was noted for the treatment group from baseline to time 1, and was retained at time 2. The group was divided by age, with those 11.0 years and younger comprising one group and those older the second group. This analysis indicated that the major reduction in depressive symptoms occurred in those over 11 years old. When divided by age, a second unexpected finding emerged. There was a significant increase in attention-deficit\/hyperactivity disorder symptoms from baseline to 24 months in those children 11 and under, independent of treatment status. The groups were subsequently further broken down by sex and by genetic status (deletion versus disomy) with no significant findings. At no time was the expected behavioral deterioration reported. We conclude that in addition to the previously detailed improvements in physical parameters for these children, behavioral improvement, including a lack of predictable behavioral deterioration during the treatment period, is a strong argument for the use of GHRT for this difficult syndrome.<\/jats:p>","DOI":"10.1542\/peds.109.2.e35","type":"journal-article","created":{"date-parts":[[2004,8,14]],"date-time":"2004-08-14T00:17:55Z","timestamp":1092442675000},"page":"e35-e35","source":"Crossref","is-referenced-by-count":67,"title":["The Behavioral Impact of Growth Hormone Treatment for Children and Adolescents With Prader-Willi Syndrome: A 2-Year, Controlled Study"],"prefix":"10.1542","volume":"109","author":[{"given":"Barbara Y.","family":"Whitman","sequence":"first","affiliation":[{"name":"St Louis University School of Medicine and Cardinal Glennon Pediatric Research Institute, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Myers","sequence":"additional","affiliation":[{"name":"St Louis University School of Medicine and Cardinal Glennon Pediatric Research Institute, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Carrel","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Wisconsin, Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Allen","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Wisconsin, Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2002,2,1]]},"reference":[{"key":"2021121006141604900_R1","unstructured":"Prader A, Labhart A, Willi H. Ein syndrom von adipositas, kleinwuchs, kryptorchismus, und oligophrnie nach myatonieartigem zustand im neugeborenenalter. Schweizerische Med Wochenschr.1956;8:1260\u20131261"},{"key":"2021121006141604900_R2","doi-asserted-by":"crossref","unstructured":"Zellweger H, Schneider HJ. Syndrome of hypotonia-hypomentia-hypogonadism-obesity (HHHO) or Prader-Willi syndrome. J Dis Child.1968;115:588\u2013598","DOI":"10.1001\/archpedi.1968.02100010590009"},{"key":"2021121006141604900_R3","unstructured":"Zellweger H. Diagnosis and therapy in the first phase of Prader-Willi syndrome. In: Holm V, Sulzbacher SJ, Pipes PL, eds. The Prader Willi Syndrome.Baltimore, MD: University Park Press;1981:55\u201368"},{"key":"2021121006141604900_R4","doi-asserted-by":"crossref","unstructured":"Butler M. Prader-Willi syndrome: current understanding of cause and diagnosis. Am J Med Genet.1990;35:319\u2013332","DOI":"10.1002\/ajmg.1320350306"},{"key":"2021121006141604900_R5","doi-asserted-by":"crossref","unstructured":"Lee P, Hwu K, Henson et al. Body composition studies in Prader-Willi syndrome (PWS): effects of growth hormone (GH) therapy. In: Ellis KJ, Eastman JD, eds. Human Body Composition. In Vitro Methods, Models, and Applications. Newark, NJ: Plenum Press;1993:201\u2013206","DOI":"10.1007\/978-1-4899-1268-8_46"},{"key":"2021121006141604900_R6","doi-asserted-by":"crossref","unstructured":"Brambilla P, Bosio L, Manzoni P, et al. Peculiar body composition in patients with Prader-Labhart-Willi syndrome. Am J Clin Nutr.1997;65:1369\u20131374","DOI":"10.1093\/ajcn\/65.5.1369"},{"key":"2021121006141604900_R7","doi-asserted-by":"crossref","unstructured":"Eiholzer U, Gisin R, Weinmann C, et al. Treatment with human growth hormone in patients with Prader-Labhart-Willi syndrome reduces body fat and increases muscle mass and physical performance. Eur J Pediatr.1998;157:368\u2013377","DOI":"10.1007\/s004310050832"},{"key":"2021121006141604900_R8","doi-asserted-by":"crossref","unstructured":"Carrel A, Myers S, Whitman B, Allen DB. Growth hormone improves body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome: a controlled study. J Pediatr.1999;134:215\u2013221","DOI":"10.1016\/S0022-3476(99)70418-X"},{"key":"2021121006141604900_R9","doi-asserted-by":"crossref","unstructured":"Myers SE, Carrel AL, Whitman BY, Allen DB. Physical effects of growth hormone treatment in children with Prader-Willi syndrome. Acta Paediatr Suppl.1999;433:112\u2013114","DOI":"10.1111\/j.1651-2227.1999.tb14417.x"},{"key":"2021121006141604900_R10","doi-asserted-by":"crossref","unstructured":"Lindgren AC, Hagenas L, Muller J, et al. Growth hormone treatment of children with Prader-Willi syndrome affects linear growth and body composition favourably. Acta Paediatr.1998;87:28\u201331","DOI":"10.1111\/j.1651-2227.1998.tb01380.x"},{"key":"2021121006141604900_R11","doi-asserted-by":"crossref","unstructured":"Davies PSW. Body composition in Prader-Willi syndrome: assessment and effects of growth hormone administration. Acta Paediatr Suppl.1999;433:105\u2013108","DOI":"10.1111\/j.1651-2227.1999.tb14415.x"},{"key":"2021121006141604900_R12","doi-asserted-by":"crossref","unstructured":"Stabler B, Siegel P, Clopper R. Growth hormone deficiency in children has psychological and education co-morbidity. Clin Pediatr.1991;30:156\u2013160","DOI":"10.1177\/000992289103000304"},{"key":"2021121006141604900_R13","doi-asserted-by":"crossref","unstructured":"Sandberg D, Brook A, Campos S. Short stature: a psychosocial burden requiring growth hormone therapy?Pediatrics.1994;94:832\u2013840","DOI":"10.1542\/peds.94.6.832"},{"key":"2021121006141604900_R14","doi-asserted-by":"crossref","unstructured":"Burman P, Broman J, Hetta J, et al. Quality of life in adults with growth hormone (GH) deficiency: response to treatment with recombinant human GH in a placebo-controlled 21-month trial. J Clin Endocrinol Metab.1995;80:3585\u20133590","DOI":"10.1210\/jc.80.12.3585"},{"key":"2021121006141604900_R15","doi-asserted-by":"crossref","unstructured":"Wiren L, Bengtsson B, and Johannsson G. Beneficial effect of long-term GH replacement therapy on quality of life in adults with GH deficiency. Clin Endocrinol.1998;48:613\u2013620","DOI":"10.1046\/j.1365-2265.1998.00462.x"},{"key":"2021121006141604900_R16","doi-asserted-by":"crossref","unstructured":"Stabler B, Siegel P, Clopper R, et al. Behavior change after growth hormone of children with short stature. J Pediatr.1998;133:366\u2013373","DOI":"10.1016\/S0022-3476(98)70271-9"},{"key":"2021121006141604900_R17","unstructured":"Sulzbacker S, Crnic KA, Snow J. Behavioral and cognitive disabilities in Prader-Willi syndrome. In: Holm VA, Sulzbacher SJ, Pipes PL, eds. The Prader-Willi Syndrome. Baltimore, MD: University Park Press;1981:147\u2013160"},{"key":"2021121006141604900_R18","unstructured":"Curfs L, Verhulst F, Fryns JP. Behavioral and emotional problems in youngsters with Prader-Willi syndrome. Genet Counseling.1991;2:33\u201341"},{"key":"2021121006141604900_R19","doi-asserted-by":"crossref","unstructured":"Whitman B, Accardo P. Emotional symptoms in Prader-Willi syndrome adolescents. Am J Med Genet.1987;28:897\u2013905","DOI":"10.1002\/ajmg.1320280415"},{"key":"2021121006141604900_R20","doi-asserted-by":"crossref","unstructured":"Whitman B, Accardo P. Prader-Willi syndrome [letter]. J Royal Soc Med.1989;82:448","DOI":"10.1177\/014107688908200738"},{"key":"2021121006141604900_R21","doi-asserted-by":"crossref","unstructured":"Myers S, Carrel A, Whitman B, Allen D. Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome. J Pediatr.2000;137:42\u201349","DOI":"10.1067\/mpd.2000.105369"},{"key":"2021121006141604900_R22","doi-asserted-by":"crossref","unstructured":"Boyle MH, Offord DR, Racine Y, et al. Evaluation of the revised Ontario Child Health Study scales. J Child Psychol Psychiatry.1993;34:189\u2013213","DOI":"10.1111\/j.1469-7610.1993.tb00979.x"},{"key":"2021121006141604900_R23","doi-asserted-by":"crossref","unstructured":"Whitman B, Greenswag L. Psychological and behavioral management. In: Greenswag L, Alexander R, eds. Management of Prader-Willi Syndrome. 2nd ed. New York, NY: Springer-Verlag;1995:125\u2013141","DOI":"10.1007\/978-1-4615-7384-5_9"},{"key":"2021121006141604900_R24","unstructured":"McCubbin H, Thompson A. Family Assessment Inventories for Research and Practice. Madison, WI: Family Stress Coping and Health Project;1987:81\u201399"},{"key":"2021121006141604900_R25","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Press;1994:327"},{"key":"2021121006141604900_R26","doi-asserted-by":"crossref","unstructured":"Feurer ID, Dimitropoulos A, Stone WL, Roof E, Butler MF, Thompson T. The latent variable structure of the compulsive behavior checklist in people with Prader-Willi syndrome. J Intellect Dis Res.1998;42:472\u2013480","DOI":"10.1046\/j.1365-2788.1998.4260472.x"},{"key":"2021121006141604900_R27","unstructured":"Whitman B, Greenswag L, Boyt M. The use and impact of psychotropic medications for managing and behavior in persons with Prader-Willi syndrome. Proceedings 13th Annual Prader-Willi Association Scientific Conference; July 22, 1998; Columbus, OH"},{"key":"2021121006141604900_R28","unstructured":"Fleiss JL. Statistical Methods for Rates and Proportions. 2nd ed. New York, NY: Wiley and Sons;1988"},{"key":"2021121006141604900_R29","doi-asserted-by":"crossref","unstructured":"Dykens E, Hodapp R, Walsh K, Nash L. Adaptive and maladaptive behavior in Prader-Willi syndrome. J Am Acad Child Adolesc Psychiatry.1992;31:1131\u20131136","DOI":"10.1097\/00004583-199211000-00023"},{"key":"2021121006141604900_R30","doi-asserted-by":"crossref","unstructured":"Stabler B, Siegel P, Clopper R, Stoppani C, Compton P, Underwood L. Reply to the letter to the editor [letter]. J Pediatr.1999;135:134","DOI":"10.1016\/S0022-3476(99)70353-7"},{"key":"2021121006141604900_R31","doi-asserted-by":"crossref","unstructured":"Sandberg D, MacGillivray M, Clopper R, Gung C, LeRoux L, Alliger D. Quality of life among formerly treated childhood-onset growth hormone-deficient adults: a comparison with unaffected siblings. J Clin Endocrinol Metab.1998;83:1134\u20131142","DOI":"10.1210\/jc.83.4.1134"},{"key":"2021121006141604900_R32","doi-asserted-by":"crossref","unstructured":"Takano K, Tanaka T, Saito T, and the Committee for the Study Group of Adult GH Deficiency. Psychosocial adjustment in a large cohort of adults with growth hormone deficiency treated with growth hormone in childhood: summary of a questionnaire survey. Acta Paediatr Suppl.1994;399:16\u20131","DOI":"10.1111\/j.1651-2227.1994.tb13278.x"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/109\/2\/e35\/1113789\/pe0202000e35.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/109\/2\/e35\/1113789\/pe0202000e35.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T14:07:32Z","timestamp":1639145252000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/109\/2\/e35\/63942\/The-Behavioral-Impact-of-Growth-Hormone-Treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2,1]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2002,2,1]]},"published-print":{"date-parts":[[2002,2,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.109.2.e35","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,2,1]]}}}